BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15129424)

  • 1. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
    Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
    Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T; Gehani N; Katz A
    Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
    Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
    Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin.
    Kim JH; Xu C; Keum YS; Reddy B; Conney A; Kong AN
    Carcinogenesis; 2006 Mar; 27(3):475-82. PubMed ID: 16299382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
    Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
    Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; RĂ©dini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.
    Nakamura K; Yasunaga Y; Segawa T; Ko D; Moul JW; Srivastava S; Rhim JS
    Int J Oncol; 2002 Oct; 21(4):825-30. PubMed ID: 12239622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells.
    Ji C; Cao C; Lu S; Kivlin R; Amaral A; Kouttab N; Yang H; Chu W; Bi Z; Di W; Wan Y
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):857-65. PubMed ID: 18214481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
    Chen A; Xu J
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.